StockIQpro
NASDAQ:RYTM

Rhythm Pharmaceuticals, Inc.

Track all markets on TradingView
Track all markets on TradingView

Rhythm Pharmaceuticals, Inc.'s revenue grew 45.8% in fiscal 2025 to $189.8M while operating margin rose to −101.2%, its highest in 5 years. Free cash flow was −$116.6M, −61.5% of revenue, and the diluted share count rose 6.5%.Summary generated from Rhythm Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$189.8M
Revenue growth+45.8%
Revenue, 5-yr CAGRn/a
Gross margin89.7%
Operating margin−101.2%
Net margin−103.6%
ROIC−128.9%
Return on equity−244.5%
Debt / equity0.78
Free cash flow−$116.6M
FCF margin−61.5%
Share count change+6.5%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue32477130190
Operating income−170−179−184−266−192
Net income−70−181−185−261−197
Free cash flow−146−174−136−114−117

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations